1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

Gadgeel, S.M. ; Mok, T.S.K. ; Peters, S. ; Nadal, E. ; Han, J-Y. ; Alatorre Alexander, J.A. ; Leighl, N. ; Sriuranpong, V. ; Pérol, M. ; Castro, G.D. ; de Marinis, F. ; Tan, D.S.W. ; Paul, S. ; Assaf, Z.J. ; MacLennan, M. ; Lohmann, T.O. ; Slade, M. ; Mathisen, M.S. ; Bhagawati-Prasad, V. ; Dziadziuszko, R.

Elsevier Ltd

Sem texto completo

9P Final results from TAIL: Updated long-term safety and efficacy of atezolizumab (atezo) in a diverse population of patients (pts) with previously treated advanced NSCLC

Ardizzoni, A. ; Azevedo, S. ; Rubio-Viqueira, B. ; Rodriguez-Abreu, D. ; Alatorre-Alexander, J. ; Smit, H.J.M. ; Yu, J. ; Syrigos, K. ; Hoglander, E. ; Kaul, M. ; Tolson, J. ; Hu, Y. ; Vollan, H.K. ; Newsom-Davis, T.

Texto completo disponível

LBA59 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

Johnson, M. ; Cho, B.C. ; Luft, A. ; Alatorre-Alexander, J. ; Geater, S.L. ; Laktionov, K. ; Kim, S-W. ; Ursol, G. ; Hussein, M. ; Lim, F.L. ; Yang, C.T. ; Araujo, L.H. ; Saito, H. ; Reinmuth, N. ; Lai, Z. ; Mann, H. ; Shi, X. ; Peters, S. ; Garon, E. ; Mok, T.S.K.

Texto completo disponível

5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON

Garon, E.B. ; Cho, B.C. ; Luft, A. ; Alatorre-Alexander, J. ; Geater, S.L. ; Trukhin, D. ; Kim, S-W. ; Ursol, G. ; Hussein, M. ; Lim, F.L. ; Yang, C-T. ; Araujo, L.H. ; Saito, H. ; Reinmuth, N. ; Medic, N. ; Mann, H. ; Shi, X. ; Peters, S. ; Mok, T.S.K. ; Johnson, M.

Texto completo disponível

326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

Cho, B.C. ; Luft, A. ; Alatorre Alexander, J.A. ; Lucien Geater, S. ; Laktionov, K. ; Sang-We, K. ; Ursol, G. ; Hussein, M. ; Lim Farah, L. ; Yang, C.T. ; Araujo, L.H. ; Saito, H. ; Reinmuth, N. ; Lai, Z. ; Mann, H. ; Shi, X. ; Peters, S. ; Garon, E.B. ; Mok, T.S.K. ; Johnson, M.L.

Texto completo disponível

1736O - IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

Reck, M. ; Liu, S.V. ; Mansfield, A.S. ; Mok, T.S.K. ; Scherpereel, A. ; Reinmuth, N. ; Garassino, M.C. ; De Carpeno, JCastro ; Califano, R. ; Nishio, M. ; Orlandi, F. ; Alexander, J A Alatorre ; Leal, T.A. ; Cheng, Y. ; Lee, J.-S. ; Lam, S. ; McCleland, M. ; Deng, Y. ; Phan, S. ; Horn, L.

Elsevier Ltd

Texto completo disponível

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

Reck, M. ; Liu, S.V. ; Mansfield, A.S. ; Mok, T.S.K. ; Scherpereel, A. ; Reinmuth, N. ; Garassino, M.C. ; De Carpeno, JCastro ; Califano, R. ; Nishio, M. ; Orlandi, F. ; Alexander, J A Alatorre ; Leal, T.A. ; Cheng, Y. ; Lee, J.-S. ; Lam, S. ; McCleland, M. ; Deng, Y. ; Phan, S. ; Horn, L.

Texto completo disponível

1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

Reck, M ; Liu, S V ; Mansfield, A S ; Mok, T S K ; Scherpereel, A ; Reinmuth, N ; Garassino, M C ; Carpeno, J De Castro ; Califano, R ; Nishio, M ; Orlandi, F ; Alexander, J A Alatorre ; Leal, T A ; Cheng, Y ; Lee, J-S ; Lam, S ; McCleland, M ; Deng, Y ; Phan, S ; Horn, L

Oxford University Press

Texto completo disponível